The diffuse large B-cell lymphoma (DLBCL) market was valued at USD 4.7 billion across the leading markets (the US, EU4, UK, and Japan) in 2024. In the United States, the market is projected to exceed USD 11.5 billion by 2034, driven by factors such as increased adoption and expanded use of approved CAR-T therapies and bispecific antibodies in earlier treatment lines. The DLBCL drug development pipeline encompasses various classes, including allogeneic CAR-Ts, monoclonal antibodies, and bispecifics, along with novel mechanisms of action such as PKC β inhibitors, BTK inhibitors, SYK inhibitors, CD30-directed antibody-drug conjugates, immunotherapies, and others.
DelveInsight’s Diffuse Large B-cell Lymphoma Market Insights report provides a comprehensive overview of current treatment practices, emerging DLBCL therapies, market share of individual treatments, and the current and projected market size from 2020 to 2034, segmented across leading markets [the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].
Diffuse Large B-cell Lymphoma Market Report Summary
- The DLBCL market was valued at USD 4.7 billion across the leading markets (US, EU4, UK, and Japan) in 2024.
- Key companies active in the DLBCL market, including BMS, Roche (Genentech), Biogen, Nektar Therapeutics, Merck, Allogene Therapeutics, Miltenyi Biomedicine, AstraZeneca, BioVaxys, ImmunoVaccine Technologies, Cellectar Biosciences, Galapagos, Novartis, Lyell, ImmPACT Bio, Pfizer, Kartos Therapeutics, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Ranok Therapeutics, Constellation Pharmaceuticals, Genmab, IDP Discovery Pharma S.L., Immunitas Therapeutics, Monte Rosa Therapeutics, SymBio Pharmaceuticals, Eagle Pharma, AVM Biotechnology, Autolus Therapeutics, Kymera Therapeutics, Otsuka Pharmaceutical, Caribou Biosciences, Adicet Bio, Gilead Sciences, Xynomic Pharmaceuticals, Amgen, and others, are expected to launch therapies during the forecast period.
- Emerging DLBCL therapies, such as Zilovertamab vedotin (Merck), Zamtocabtagene autoleucel (Miltenyi Biomedicine), Cemacabtagene ansegedleucel (Allogene Therapeutics), Rapcabtagene autoleucel (Novartis), Golcadomide (BMS), and others, are anticipated to enter the market by 2034, potentially transforming the treatment landscape.
- Label expansions of already approved therapies such as EPKINLY/TEPKINLY, COLUMVI, KEYTRUDA, MONJUVI/MINJUVI, POLIVY, YESCARTA, BREYANZI, KYMRIAH, and others are expected to contribute to market growth, supported by an increasing DLBCL patient population.
- Frontline treatment: Approximately 60% of DLBCL patients achieve remission with R-CHOP therapy, while 40% either relapse or are refractory. These patients traditionally receive salvage chemotherapy with regimens like R-GemOx, R-ICE, or R-DHAP, though no regimen has shown clear superiority.
- CAR T-cell therapies: YESCARTA (axicabtagene ciloleucel), BREYANZI (lisocabtagene maraleucel), and KYMRIAH (tisagenlecleucel) are FDA-approved for relapsed or refractory DLBCL, but none are approved for first-line use. Gilead/Kite is evaluating YESCARTA in the first-line setting, which could introduce significant competition.
- Third-line therapies: EPKINLY (epcoritamab-bysp) and COLUMVI (glofitamab-gxbm), approved in 2023, provide innovative options for third-line treatment of LBCL. EPKINLY has shown stronger uptake due to approvals across the US, Europe, and Japan, whereas COLUMVI is approved only in the US and Europe.
- Allogeneic CAR T therapy: Cemacabtagene ansegedleucel (Allogene Therapeutics) is an off-the-shelf, allogeneic CD19 CAR T-cell therapy in the Phase II ALPHA3 trial, investigating its role as first-line consolidation in LBCL patients with measurable residual disease (MRD) post-standard treatment. Its potential market entry could represent a breakthrough option in the DLBCL treatment landscape.
Explore more about the diffuse large B-cell lymphoma treatment market @ Diffuse Large B-cell Lymphoma Medication
Key Factors Driving the Growth of Diffuse Large B-cell Lymphoma Market
Increasing DLBCL Incidence and Aging Population
Global DLBCL incidence exceeds 150,000 cases annually, driven by aging populations (9% aged 65+). In the 7MM, incident cases are projected to reach ~87K by 2034.
Launch of Emerging Targeted DLBCL Therapies and Immunotherapies
The introduction of novel treatment options, such as CAR-T therapies (Allogene Therapeutics’s Cemacabtagene ansegedleucel, Miltenyi Biomedicine’s Zamtocabtagene autoleucel, Galapagos’s GLPG5101, Novartis’ Rapcabtagene Autoleucel, Lyell/ImmPACT Bio’s IMPT-314, and others), monoclonal antibodies (Genmab’s GEN3014), and bispecific antibodies (Roche/Biogen’s LUNSUMIO, AstraZeneca’s AZD0486, and others), is expected to propel the DLBCL treatment market.
Growing Investment in R&D and DLBCL Clinical Trials
More than 30 pharmaceutical DLBCL companies, including Roche (Genentech), Biogen, AstraZeneca, Merck, Allogene Therapeutics, Novartis, Pfizer, 2seventy bio, Regeneron Pharmaceuticals, BeiGene, Bristol-Myers Squibb, Otsuka Pharmaceutical, Gilead Sciences, Amgen, and others, are investing heavily in developing next-generation DLBCL therapies, resulting in a stronger pipeline and more approvals.
Improved DLBCL Diagnostic Capabilities and Early Detection
Improved diagnostic tools, such as PET-CT and next-generation sequencing, have boosted early detection rates in DLBCL by nearly 20%, enabling risk stratification and personalized treatment approaches. Early-stage diagnosis now accounts for approximately 35–40% of identified cases, resulting in significantly improved survival outcomes.
Diffuse Large B-cell Lymphoma Treatment Market Analysis
The DLBCL treatment landscape is witnessing significant growth, driven by evolving therapeutic options and advancements in targeted therapies. The R-CHOP regimen, comprising rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, continues to serve as the standard first-line therapy, particularly for newly diagnosed patients. However, patients with high-risk disease profiles are increasingly receiving more intensive or combination strategies, such as R-CHOP with agents like lenalidomide or bortezomib, which is expanding treatment adoption and driving market growth.
For indolent lymphomas, management strategies range from watchful waiting to radiotherapy or chemotherapy, while aggressive lymphomas demand intensive chemotherapy protocols often supplemented with prophylactic measures to prevent central nervous system (CNS) involvement. The emphasis on multidisciplinary care and supportive therapies to mitigate side effects is further enhancing patient outcomes and influencing market uptake.
The relapsed and refractory DLBCL segment is particularly propelling market expansion, fueled by the introduction of innovative CD19-directed CAR-T therapies. FDA-approved therapies such as YESCARTA and BREYANZI, available since 2022, have rapidly become preferred options for early-relapsed, high-risk patients, highlighting a shift toward precision medicine. Similarly, KYMRIAH, approved for adult patients with relapsed or refractory large B-cell lymphoma (including DLBCL, high-grade B-cell lymphoma, and DLBCL transformed from follicular lymphoma), is contributing to market momentum, although it is not indicated for primary CNS lymphoma.
The growing adoption of these CAR-T cell therapies, coupled with expanding indications and continued R&D investment in next-generation immunotherapies, is expected to further accelerate the DLBCL treatment market. As patient access improves and therapeutic outcomes continue to advance, the market is poised for sustained growth, underscoring the transformative impact of targeted and personalized therapies in hematologic oncology.
Learn more about FDA-approved drugs for diffuse large B-cell lymphoma @ Diffuse Large B-cell Lymphoma Treatment
Diffuse Large B-cell Lymphoma Competitive Landscape
DelveInsight’s analysts report that approximately 30 companies are actively developing therapies in the DLBCL space. Key pipeline drugs include Zamtocabtagene Autoleucel (MB-CART2019.1) (Miltenyi Biomedicine), AZD0486 (AstraZeneca), Maveropepimut-S (BioVaxys/ImmunoVaccine Technologies), Cemacabtagene ansegedleucel (cema-cel) (Allogene Therapeutics), IMPT-314 (Lyell/ImmPACT Bio), and others.
Miltenyi Biomedicine is advancing a CAR T-cell therapy for adult patients with relapsed or refractory DLBCL who have undergone at least one prior line of therapy. Zamtocabtagene autoleucel (Zamto-Cel) is distinctive due to its dual targeting of CD19 and CD20 proteins on B cells. This investigational therapy has been recognized under the European Union’s Priority Medicines (PRIME) scheme for its potential. In August 2020, Miltenyi Biomedicine received Orphan Drug Designation (ODD) from the European Commission for MB-CART2019.1 in DLBCL. Interim results from the Phase II DALY II USA trial of Zamto-Cel in relapsed/refractory DLBCL patients were presented in December 2024.
AZD0486 is an innovative IgG4, fully human CD19 x CD3 bispecific T-cell engager (TCE) designed with low-affinity CD3 binding to minimize cytokine release while maintaining potent T-cell-mediated cytotoxicity against cancerous B cells. The therapy demonstrated activity and was well tolerated in patients with relapsed or refractory B-cell non-Hodgkin lymphoma, including DLBCL.
The anticipated launch of these emerging DLBCL therapies is expected to transform the market landscape in the coming years. As these cutting-edge therapies mature and gain regulatory approval, they are poised to reshape DLBCL treatment standards, driving medical innovation and creating significant economic opportunities.
Explore diffuse large B-cell lymphoma drugs in development @ Diffuse Large B-cell Lymphoma Clinical Trials
Recent Developments in the Diffuse Large B-cell Lymphoma Market
- In June 2025, Genmab announced that epcoritamab in combination with rituximab, ifosfamide, carboplatin, and etoposide (R-ICE) demonstrates high response rates in patients with relapsed/refractory (R/R) DLBCL eligible for autologous stem cell transplantation.
- In April 2025, the European Commission approved COLUMVI in combination with gemcitabine and oxaliplatin for adult patients with relapsed or refractory DLBCL not otherwise specified who are ineligible for autologous stem cell transplant.
- In March 2025, Imugene received FDA Fast Track designation for its allogeneic CAR T-cell therapy, azer-cel (azercabtagene zapreleucel), for treating relapsed or refractory DLBCL.
- In February 2025, the US FDA approved ADCETRIS in combination with lenalidomide and a rituximab product for adult patients with relapsed or refractory large B-cell lymphoma (LBCL), including DLBCL not otherwise specified (NOS), DLBCL arising from indolent lymphoma, or high-grade B-cell lymphoma (HGBL), after two or more lines of systemic therapy who are ineligible for autologous hematopoietic stem cell transplantation (auto-HSCT) or CAR T-cell therapy.
Diffuse Large B-cell Lymphoma Epidemiology Segmentation
The latest report provides detailed insights into the DLBCL patient pool, incident cases, and projected growth through 2034. Analysts estimate that incident cases in the 7MM will reach approximately 87K by 2034. The epidemiology section provides historical and current DLBCL patient data, along with forecasted trends, helping to identify the drivers behind current and future patient population changes through studies and insights from key opinion leaders.
The diffuse large B-cell lymphoma market report includes epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
- Total Incident Cases of DLBCL
- Gender-specific Cases of DLBCL
- Age-specific Cases of DLBCL
- Type-specific Cases of DLBCL
- Stage-specific Incident Cases of DLBCL
Scope of the Diffuse Large B-cell Lymphoma Market Report
- DLBCL Therapeutic Assessment: Current marketed and emerging therapies
- Diffuse Large B-cell Lymphoma Market Dynamics: Key market forecast assumptions for emerging DLBCL drugs and market outlook
- Competitive Intelligence Analysis: SWOT analysis, Conjoint analysis, and market entry strategies
- Unmet Needs, KOL’s Views, Analyst’s Views, Market Access and Reimbursement
Get the report to explore diffuse large B-cell lymphoma market trends @ Diffuse Large B-cell Lymphoma Market Report
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions.
